Rafael Holdings (Rafael Holdings) ROCE % : -12.73% (As of Jan. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Rafael Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rafael Holdings's annualized ROCE % for the quarter that ended in Jan. 2024 was -12.73%.

Rafael Holdings ROCE % Historical Data

The historical data trend for Rafael Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rafael Holdings ROCE % Chart

Rafael Holdings Annual Data

Trend

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

ROCE %

Get a 7-Day Free Trial

-3.34

-6.24

-17.51

-119.61

-9.02

Rafael Holdings Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															-17.33	-7.35	6.11	-10.37	-12.73

Rafael Holdings ROCE % Calculation

Rafael Holdings's annualized ROCE % for the fiscal year that ended in Jul. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jul. 2023 )		(A: Jul. 2022 )		(A: Jul. 2023 )
	=	-8.745	/	( ( (118.32 - 21.026)	+	(98.829 - 2.145) )	/ 2 )
	=	-8.745	/	( (97.294	+	96.684)	/ 2 )
	=	-8.745	/	96.989
	=	-9.02 %

Rafael Holdings's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-12.572	/	( ( (95.502 - 0.934)	+	(106.149 - 3.263) )	/ 2 )
	=	-12.572	/	( ( 94.568	+	102.886 )	/ 2 )
	=	-12.572	/	98.727
	=	-12.73 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

Rafael Holdings (NYSE:RFL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rafael Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Rafael Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rafael Holdings (Rafael Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Rafael Holdings Inc (NYSE:RFL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

520 Broad Street, Newark, NJ, USA, 07102

Website

https://www.rafaelholdings.com

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Executives

I9 Plus, Llc	10 percent owner	153 BOOTH AVE, ENGLEWOOD NJ 07631
Howard S Jonas	director
Mary Margaret Huizinga	officer: Chief Devel. & Medical Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Ashok D Marin	officer: Chief Legal Officer	C/O LIPOSCIENCE, INC., 2500 SUMNER BOULEVARD, RALEIGH NC 27616
Patrick Fabbio	officer: Chief Financial Officer	2 PITNEY COURT, BASKING RIDGE NJ 07920
Mark Anthony Mccamish	director	C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Shannon Thyme Klinger	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Ameet Mallik	officer: CHIEF EXECUTIVE OFFICER	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
William Conkling	officer: Chief Commercial Officer	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Rachel Jonas	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Boris C Pasche	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Michael J Weiss	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
Stephen M Greenberg	director	C/O NET2PHONE INC, 520 BROAD ST, NEWARK NJ 07102
David Polinsky	officer: Chief Financial Officer	90 BOOTH AVENUE, ENGLEWOOD NJ 07631
Menachem Ash	director, officer: President	C/O IDT CORPORATION, 520 BROAD STREET, NEWARK NJ 07102